BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim JK, Kim HD, Jun MJ, Yun SC, Shim JH, Lee HC, Lee D, An J, Lim YS, Chung YH, Lee YS, Kim KM. Tumor Volume Doubling Time as a Dynamic Prognostic Marker for Patients with Hepatocellular Carcinoma. Dig Dis Sci 2017;62:2923-31. [PMID: 28815349 DOI: 10.1007/s10620-017-4708-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Mendiratta-Lala M, Masch W, Shankar PR, Hartman HE, Davenport MS, Schipper MJ, Maurino C, Cuneo KC, Lawrence TS, Owen D. Magnetic Resonance Imaging Evaluation of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy: Long Term Imaging Follow-Up. Int J Radiat Oncol Biol Phys 2019;103:169-79. [PMID: 30213751 DOI: 10.1016/j.ijrobp.2018.09.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
2 Singal AG. Reply. Gastroenterology 2019;157:901-2. [PMID: 31306633 DOI: 10.1053/j.gastro.2019.07.011] [Reference Citation Analysis]
3 Park BV, Gaba RC, Huang YH, Chen YF, Guzman G, Lokken RP. Histology of Hepatocellular Carcinoma: Association with Clinical Features, Radiological Findings, and Locoregional Therapy Outcomes. J Clin Imaging Sci 2019;9:52. [PMID: 31819829 DOI: 10.25259/JCIS_111_2019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Huo J, Wu L, Zang Y. A robust nine-gene prognostic signature associated with tumour doubling time for hepatocellular carcinoma. Life Sci 2020;260:118396. [PMID: 32918973 DOI: 10.1016/j.lfs.2020.118396] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
5 Rich NE, John BV, Parikh ND, Rowe I, Mehta N, Khatri G, Thomas SM, Anis M, Mendiratta-Lala M, Hernandez C, Odewole M, Sundaram LT, Konjeti VR, Shetty S, Shah T, Zhu H, Yopp AC, Hoshida Y, Yao FY, Marrero JA, Singal AG. Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis. Hepatology 2020;72:1654-65. [PMID: 32017165 DOI: 10.1002/hep.31159] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 28.5] [Reference Citation Analysis]
6 Oh H, Kwon H, Song E, Jeon MJ, Kim TY, Lee JH, Kim WB, Shong YK, Chung K, Baek JH, Kim WG. Tumor Volume Doubling Time in Active Surveillance of Papillary Thyroid Carcinoma. Thyroid 2019;29:642-9. [DOI: 10.1089/thy.2018.0609] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 6.3] [Reference Citation Analysis]
7 Purcell Y, Sartoris R, Paradis V, Vilgrain V, Ronot M. Influence of pretreatment tumor growth rate on objective response of hepatocellular carcinoma treated with transarterial chemoembolization. J Gastroenterol Hepatol 2020;35:305-13. [PMID: 31369166 DOI: 10.1111/jgh.14816] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
8 Fuller SN, Shafiei A, Venzon DJ, Liewehr DJ, Mauda Havanuk M, Ilanchezhian MG, Edgerly M, Anderson VL, Levy EB, Hoang CD, Jones EC, Reilly KM, Widemann BC, Wood BJ, Bagheri H, Del Rivero J. Tumor Doubling Time Using CT Volumetric Segmentation in Metastatic Adrenocortical Carcinoma. Curr Oncol 2021;28:4357-66. [PMID: 34898541 DOI: 10.3390/curroncol28060370] [Reference Citation Analysis]
9 Miura K, Hamanaka K, Koizumi T, Kawakami S, Kobayashi N, Ito KI. Solid component tumor doubling time is a prognostic factor in non-small cell lung cancer patients. J Cardiothorac Surg 2019;14:57. [PMID: 30871590 DOI: 10.1186/s13019-019-0879-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
10 Zhang G, Su L, Lv X, Yang Q. A novel tumor doubling time-related immune gene signature for prognosis prediction in hepatocellular carcinoma. Cancer Cell Int 2021;21:522. [PMID: 34627241 DOI: 10.1186/s12935-021-02227-w] [Reference Citation Analysis]
11 Devcic Z, Elboraey M, Vidal L, Mody K, Harnois D, Patel T, Toskich BB. Individualized Ablation of Hepatocellular Carcinoma: Tailored Approaches across the Phenotype Spectrum. Semin Intervent Radiol 2019;36:287-97. [PMID: 31680719 DOI: 10.1055/s-0039-1698755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Nathani P, Gopal P, Rich N, Yopp A, Yokoo T, John B, Marrero J, Parikh N, Singal AG. Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis. Gut 2021;70:401-7. [PMID: 32398224 DOI: 10.1136/gutjnl-2020-321040] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 13.0] [Reference Citation Analysis]
13 Wong VC, Wong MI, Lam CT, Lung ML, Lam KO, Lee VH. Hallmark microRNA signature in liquid biopsy identifies hepatocellular carcinoma and differentiates it from liver metastasis. J Cancer 2021;12:4585-94. [PMID: 34149922 DOI: 10.7150/jca.59933] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Krishan S, Dhiman RK, Kalra N, Sharma R, Baijal SS, Arora A, Gulati A, Eapan A, Verma A, Keshava S, Mukund A, Deva S, Chaudhary R, Ganesan K, Taneja S, Gorsi U, Gamanagatti S, Madhusudan KS, Puri P, Shalimar, Govil S, Wadhavan M, Saigal S, Kumar A, Thapar S, Duseja A, Saraf N, Khandelwal A, Mukhopadyay S, Gulati A, Shetty N, Verma N. Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System. J Clin Exp Hepatol 2019;9:625-51. [PMID: 31695253 DOI: 10.1016/j.jceh.2019.07.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Lee DD, Sapisochin G, Mehta N, Gorgen A, Musto KR, Hajda H, Yao FY, Hodge DO, Carter RE, Harnois DM. Surveillance for HCC After Liver Transplantation: Increased Monitoring May Yield Aggressive Treatment Options and Improved Postrecurrence Survival. Transplantation 2020;104:2105-12. [PMID: 31972705 DOI: 10.1097/TP.0000000000003117] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
16 Piccinno E, Monteduro AG, Dituri F, Rizzato S, Giannelli G, Maruccio G. Validation of a Lab-on-Chip Assay for Measuring Sorafenib Effectiveness on HCC Cell Proliferation. Int J Mol Sci 2021;22:13090. [PMID: 34884894 DOI: 10.3390/ijms222313090] [Reference Citation Analysis]
17 Colombatto P, Demirtas CO, Ricco G, Civitano L, Boraschi P, Scalise P, Cavallone D, Oliveri F, Romagnoli V, Bleve P, Coco B, Salvati A, Urbani L, Bonino F, Brunetto MR. Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib. Cancers (Basel) 2021;13:2064. [PMID: 33922938 DOI: 10.3390/cancers13092064] [Reference Citation Analysis]